This mAb reacting against carbonic anhydrase IX (CAIX), a cell-surface antigen over-expressed in the vast majority of ccRCC, was 124I-labelled and used in 26 pre-surgical patients with renal masses. Here, CA9 is linked to nonpapillary renal cell carcinoma.